Evidence map›Paper›PMID 19299624›Full record

ArticleInternational immunology2009

The effects of c-Abl mutation on developing B cell differentiation and survival.

Hans Brightbill, Mark S Schlissel

Open access · bronzeAbstract read
In one paragraph

Article in International immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hans BrightbillDivision of Immunology, Department of Molecular and Cell Biology, 439 Life Science Addition, University of California, Berkeley, CA 94720-3200, USA.
Mark S Schlissel
University of California, Berkeley · US

Funding

Molecular Immunology &Tumor BiologyT32CA009179 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI RAULET, DAVID H · 1985 to 2011
$2.5M
c-Abl and PKC-eta in Cell Development and LeukemiaR01AI057487 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI SCHLISSEL, MARK S. · 2004 to 2008
$1.8M
NCI NIH HHS T32 CA009179-31NIAID NIH HHS R01 AI57487
6 · The paper itself

Abstract

c-Abl is a widely expressed Src family protein tyrosine kinase that is activated by chromosomal translocation in certain human leukemias. While shown in various experimental systems to regulate cell division and stress responses, its biological functions remain poorly understood. Although expressed at similar levels throughout B cell development, we found that the fraction of phosphorylated, active c-Abl peaks at the pro-B stage. We went on to perform a detailed analysis of B cell development in c-Abl-deficient mice. We confirmed a striking but variable decrease in pro- and pre-B cell numbers, a decrease in pre-B cell growth and an increase in pre-B cell apoptosis. This phenotype was not rescued by transgenic expression of a functional IgHC transgene and only partially rescued by the anti-apoptosis gene Bcl-x. Unlike their wild-type counterparts, c-Abl-deficient pre-B cells show a defect in Ca(2+) flux upon cross-linking of CD19, a co-receptor known to be involved in pre-B cell receptor signaling and failed to express CD25 on the cell surface. Despite these pre-B cell-signaling defects, selection for in-frame heavy-chain rearrangements was intact in the mutant mice. Remarkably, we were able to rescue the proliferative defect by culturing cells in vitro with large amounts of rIL-7. We conclude that c-Abl is required for normal B cell differentiation and survival.

Indexed as

Cell DifferentiationAnimalsAntigens, CD19ApoptosisCalciumCell ProliferationCell SurvivalInterleukin-7MiceMice, KnockoutMutationPrecursor Cells, B-LymphoidProto-Oncogene Proteins c-ablRecombinant ProteinsTumor Suppressor Protein p53Antigens, CD19CalciumInterleukin-7Proto-Oncogene Proteins c-ablRecombinant ProteinsTumor Suppressor Protein p53

Identifiers

PMID19299624
PMCPMC2675032
OpenAlexW2134938419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.